Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

Progress at Oxford BioDynamics

Country: United Kingdom

Oxford BioDynamics (OBD) continued to reap commercial returns from its proprietary biomarker platform with revenue for the half-year ended 31 March of £0.5 million, up from £0.4 million a year earlier. The company had cash on hand of £9.6 million at the end of the period, compared with £11.5 million a year earlier.

Read more

Cancer vaccine collaboration

Country: United States

Responding to renewed interest in cancer vaccines, Merck & Co Inc and Moderna Therapeutics Inc have expanded a 2016 collaboration to develop and commercialise novel personalised messenger RNA (mRNA) vaccines.

Read more

Avacta produces protein therapeutics in mice

Country: United Kingdom

Read more

Medigene expands TCR alliance

Country: Germany

Read more

Novo embraces cell therapy

Country: Denmark

Read more

GSK reports long-term benefit of Nucala

Country: United Kingdom

Read more

Positive Phase 3 results for Dupixent

Country: France

Read more

NOXXON gives update on cancer study

Country: Germany

Read more

AZ and Emulate in drug safety alliance

Country: United Kingdom

Read more

AZ sees return to growth

Country: United Kingdom

Read more

AZ drug for COPD fails first of two Phase 3 trials

Country: United Kingdom

Read more

Growth for Lundbeck depression drugs

Country: Denmark

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

Non-governmental drug assessments in the US, by Steven Pearson

ICERStevenDPearsonContributorArticleApil2018.pdf

Highlights of the April 2018 MedNous issue

The April 2018 MedNous features:

Latest Mednous cover
  • Business Strategy
    New approach to atrial fibrillation
    Interview with Acesion Pharma
  • Research Strategy
    How genome editing is impacting cell therapy
    By Jonathan Moore
  • Public Policy
    Non-governmental drug assessments in the US
    By Steven Pearson
  • Health Technology Assessment
    The EU prepares to legislate
    By Karen Finn
  • Business Strategy
    What Roche’s takeover of Flatiron Health really means
    By Tara Raveendran
  • Commentary
    Innate Pharma aims to regain leadership in IO
    By Robin Davison
  • Gene Therapy
    Novartis pays $8.7 billion for AveXis

The latest MedNous journal. Subscribe to download.